BioSpace News Archive

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at the following virtual investor conferences in January.

Aileron Therapeutics, a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, provided a business update and outlined the company’s strategic priorities for 2022.

IceCure Medical Ltd., developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, released the following letter to shareholders from its Chief Executive Officer, Eyal Shamir.

Armata Pharmaceuticals, Inc. announces the modification of its lead bacteriophage product candidate, AP-PA02, to include additional phage genera that increase potency and broaden coverage of strains of Pseudomonas aeruginosa found in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis.

Kintara Therapeutics, Inc. announced that its Chief Executive Officer, Robert E. Hoffman will present at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

DiaCarta Inc., today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on the evaluation and development of DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology.

Elevation Oncology, Inc. (Nasdaq: ELEV), today announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology’s Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:45 a.m. ET, in a virtual format.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ operating platform, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 11:15 am ET.

Scorpion Therapeutics, Inc. has been selected by BioSpace to join its NextGen Bio “Class of 2022.” The recognition from BioSpace, a life sciences industry news outlet and career hub, highlights top up-and-coming biopharmaceutical companies to watch in the new year.

Department of Defense now able to Move Forward on Brain Plasticity Research.